Process controls are not established from validated manufacturing processes.
Inspection Record
Biotest AG — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and does not adequately identify, document, or investigate the impact to drug product.
Manufacturing building™®, where the Yimmugo drug product is manufactured, does not contain sufficient space to prevent mix-ups and to secure the product.
The (6)(4) sampling process for routinely monitoring the (b) (4) is deficient.
Strict control is not exercised over labeling materials issued for use in the Yimmugo drug product labeling operations.
Manufacturing buildings used in the manufacture ofYimmugo do not have the suitable controls to prevent contamination.
Inadequate quality oversight to assure that the Yimmugo drug product has the identity, strength, quality, and purity it purports or is represented to possess.
The manual visual inspection program is inadequate to identify))(b) (4) matter and physical defects.
Process validation is deficient as it does not cover the proposed range for process parameters that are critical.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- GSK Vaccines GmbH2024-11-12 · US FDASimilar to finding 2 Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and docs not adequately identify, document, or investigate…
- Lantheus Medical Imaging, Inc.2026-04-09 · US FDASimilar to finding 5 Strict control is not exercised over labeling issued for use in drug product labeling operations.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.